BRIDGEBIO PHARMA ($BBIO) posted quarterly earnings results for Q2 2026 on Monday, August 10th. The company reported earnings of -$0.78 per share, missing estimates of -$0.60 by $0.18. The company also reported revenue of $243,680,000, beating estimates of $223,117,676 by $20,562,324.
You can see Quiver Quantitative's $BBIO stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
BRIDGEBIO PHARMA Insider Trading Activity
BRIDGEBIO PHARMA insiders have traded $BBIO stock on the open market 75 times in the past 6 months. Of those trades, 0 have been purchases and 75 have been sales.
Here’s a breakdown of recent trading of $BBIO stock by insiders over the last 6 months:
- NEIL KUMAR (Chief Executive Officer) has made 0 purchases and 52 sales selling 374,156 shares for an estimated $26,447,042.
- JENNIFER E. COOK has made 0 purchases and 6 sales selling 278,192 shares for an estimated $21,920,434.
- ANDREA ELLIS has made 0 purchases and 2 sales selling 82,088 shares for an estimated $5,653,329.
- RANDAL W. SCOTT has made 0 purchases and 7 sales selling 20,000 shares for an estimated $1,426,012.
- THOMAS TRIMARCHI (President and CFO) has made 0 purchases and 2 sales selling 13,600 shares for an estimated $1,016,147.
- HANNAH VALANTINE has made 0 purchases and 3 sales selling 13,675 shares for an estimated $965,835.
- MARICEL APULI (Chief Accounting Officer) has made 0 purchases and 3 sales selling 4,510 shares for an estimated $341,178.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
BRIDGEBIO PHARMA Hedge Fund Activity
We have seen 235 institutional investors add shares of BRIDGEBIO PHARMA stock to their portfolio, and 221 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BLACKROCK, INC. removed 3,920,601 shares (-27.6%) from their portfolio in Q2 2026, for an estimated $292,006,362
- BROOKLANDS FUND MANAGEMENT LTD removed 2,750,000 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $204,215,000
- VIKING GLOBAL INVESTORS LP removed 2,551,500 shares (-17.7%) from their portfolio in Q1 2026, for an estimated $189,474,390
- CITADEL ADVISORS LLC added 2,475,758 shares (+354.6%) to their portfolio in Q1 2026, for an estimated $183,849,789
- JANE STREET GROUP, LLC added 1,415,877 shares (+414.2%) to their portfolio in Q1 2026, for an estimated $105,143,026
- POLAR CAPITAL HOLDINGS PLC added 1,219,960 shares (+93.9%) to their portfolio in Q1 2026, for an estimated $90,594,229
- TWO SIGMA INVESTMENTS, LP added 1,173,584 shares (+60.3%) to their portfolio in Q1 2026, for an estimated $87,150,347
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
BRIDGEBIO PHARMA Congressional Stock Trading
Members of Congress have traded $BBIO stock 5 times in the past 6 months. Of those trades, 5 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $BBIO stock by members of Congress over the last 6 months:
- REPRESENTATIVE GILBERT RAY CISNEROS, JR. has traded it 5 times. They made 5 purchases worth up to $75,000 on 05/11, 04/29, 03/19, 03/18, 03/03 and 0 sales.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.
BRIDGEBIO PHARMA Analyst Ratings
Wall Street analysts have issued reports on $BBIO in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- William Blair issued a "Outperform" rating on 03/10/2026
To track analyst ratings and price targets for BRIDGEBIO PHARMA, check out Quiver Quantitative's $BBIO forecast page.
BRIDGEBIO PHARMA Price Targets
Multiple analysts have issued price targets for $BBIO recently. We have seen 11 analysts offer price targets for $BBIO in the last 6 months, with a median target of $98.0.
Here are some recent targets:
- Salim Syed from Mizuho set a target price of $96.0 on 06/16/2026
- Whitney Ijem from Canaccord Genuity set a target price of $104.0 on 06/03/2026
- Raghuram Selvaraju from HC Wainwright & Co. set a target price of $110.0 on 05/28/2026
- Sean Laaman from Morgan Stanley set a target price of $98.0 on 05/28/2026
- Eric Joseph from Citigroup set a target price of $82.0 on 05/19/2026
- Cory Kasimov from Evercore ISI Group set a target price of $130.0 on 05/08/2026
- Danielle Brill from Truist Securities set a target price of $102.0 on 04/29/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
